Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Traditionally, medical therapy for epilepsy has aimed to suppress seizure activity, but has been unable to alter the progression of the underlying disease. Recent advances in our understanding of mechanisms of epileptogenesis open the door for the development of new therapies which prevent the pathogenic changes in the brain that predispose to spontaneous seizures. In particular, the mammalian target of rapamycin (mTOR) signaling pathway has recently garnered interest as an important regulator of cellular changes involved in epileptogenesis, and mTOR inhibitors have generated excitement as potential antiepileptogenic agents. mTOR hyperactivation occurs in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, as a result of genetic mutations in upstream regulatory molecules. mTOR inhibition prevents epilepsy and brain pathology in animal models of TSC. mTOR dysregulation has also been demonstrated in a variety of other genetic and acquired epilepsies, including brain tumors, focal cortical dysplasias, and animal models of brain injury due to status epilepticus or trauma. Indeed, mTOR inhibitors appear to possess antiepileptogenic properties in animal models of acquired epilepsy as well. Thus, mTOR dysregulation may represent a final common pathway in epilepsies of various causes. Therefore, mTOR inhibition is an exciting potential antiepileptogenic strategy with broad applications for epilepsy and could be involved in a number of treatment modalities, including the ketogenic diet. Further research is necessary to determine the clinical utility of rapamycin and other mTOR inhibitors for antiepileptogenesis, and to devise new therapeutic targets by further elucidating the signaling molecules involved in epileptogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Alterations in mTOR activity have also been identified in patients with neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease [1, 70, 85, 101, 110].”
BackgroundRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 1×
“These phosphorylate and inhibit the hamartin/tuberin complex, an important inhibitor of mTOR via the small GTPase Rheb, thus leading to increased mTOR activity [47, 71, 92, 98, 104, 120].”
BackgroundThe Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · cited 2×
“As described above, hamartin and tuberin form a complex containing a GTPase activate protein (GAP) domain that inactivates the small GTPase Rheb, thereby turning off mTOR activity [32, 39, 46, 71, 92, 98, 104, 120].”
BackgroundBrugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“Animals with mutations in TSC2, the gene encoding tuberin, are more vulnerable to oxidative and endoplasmic reticulum stress, presumably due to an inability to inhibit mTOR in these settings [10, 29].”
BackgroundMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200171200 · Cited by 851 · cited 1×
“Conversely, under conditions of energy deprivation, AMPK phosphorylates and activates tuberin to inhibit mTOR activity [7, 46, 48, 55].”
BackgroundTee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639
Self-citationRegulation of Dendritic Morphogenesis by Ras–PI3K–Akt–mTOR and Ras–MAPK Signaling Pathways
Kumar, V., Zhang, M.-X., Swank, M. W., Kunz, J., & Wu, G.-Y. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2284-05.2005 · Cited by 588
Hou, L., & Klann, E. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0995-04.2004 · Cited by 527
Anticonvulsant Mechanisms of the Ketogenic Diet
Bough, K. J., & Rho, J. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00915.x · Cited by 523
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“In neuronal development, mTOR is critical for axon guidance in response to extracellular cues, and in dendrite development and dendritic spine morphogenesis [14, 51, 58, 80, 101, 103].”
BackgroundZhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441
Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B. E., Witters, L. A., Mimura, O., & Yonezawa, K. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00615.x · Cited by 372
Uhlmann, E. J., Wong, M., Baldwin, R. L., Bajenaru, M. L., Onda, H., Kwiatkowski, D. J., Yamada, K., & Gutmann, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10283 · Cited by 372
Self-citationRole of mTOR in physiology and pathology of the nervous system
Swiech, L., Perycz, M., Malik, A., & Jaworski, J. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.015 · Cited by 338
An, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312
Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites
Raab-Graham, K. F., Haddick, P. C. G., Jan, Y. N., & Jan, L. Y. (2006) · Science · doi:10.1126/science.1131693 · Cited by 267 · cited 1×
“In the adult brain, this translates to a role of mTOR in synaptic plasticity, as mTOR has been demonstrated to regulate ion channel and neurotransmitter receptor expression [84, 112].”
BackgroundGong, R., Park, C. S., Abbassi, N. R., & Tang, S.-J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512524200 · Cited by 249 · cited 1×
“Since putative learning mechanisms, such as long term potentiation and long term depression, rely on protein synthesis for sustained changes in synaptic strength, it is not surprising that they require mTOR activity [40, 50, 102].”
BackgroundDi Nardo, A., Kramvis, I., Cho, N., Sadowski, A., Meikle, L., Kwiatkowski, D. J., & Sahin, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0778-09.2009 · Cited by 165
Do we have a cure for tuberous sclerosis complex?
Crino, P. B. (2008) · Epilepsy Currents · doi:10.1111/j.1535-7511.2008.00279.x · Cited by 10
Cited by
Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction
Goldberg, E. M., & Coulter, D. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3482 · Cited by 542
The Ketogenic Diet as a Treatment Paradigm for Diverse Neurological Disorders
Stafstrom, C. E., & Rho, J. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00059 · Cited by 438
Bateup, H. S., Johnson, C. A., Denefrio, C. L., Saulnier, J. L., Kornacker, K., & Sabatini, B. L. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.017 · Cited by 330
Commonalities in epileptogenic processes from different acute brain insults: Do they translate?
Klein, P., Dingledine, R., Aronica, E., Bernard, C., Blümcke, I., Boison, D., Brodie, M. J., Brooks‐Kayal, A. R., Engel, J., Forcelli, P. A., et al. (2018) · Epilepsia · doi:10.1111/epi.13965 · Cited by 284
Gobira, P. H., Vilela, L. R., Gonçalves, B. D. C., Santos, R. P. M., de Oliveira, A. C., Vieira, L. B., Aguiar, D. C., Crippa, J. A., & Moreira, F. A. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.08.007 · Cited by 89
Metadata
- Authors
- McDaniel, S. S., & Wong, M.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 497
- Issue
- 3
- Pages
- 231-239
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2061460624
- Cited by
- 76
- References
- 26
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.